Antiviral drug developer Chimerix, in the midst of plans for an initial public offering of stock, is building out its executive team.
Former Pharmasset executive Michael Rogers is joining the Research Triangle Park company as chief development officer overseeing chemistry, manufacturing, toxicology and project management. He’ll also be responsible for advancing the development of compounds from Chimerix’s chemical library.
Rogers was formerly the chief development officer at New Jersey-based Pharmasset. He has also worked in antiviral discovery and development at GlaxoSmithKline (NYSE:GSK); as vice president, division of viral diseases, his work included antiviral discovery activities in human immunodeficiency virus (HIV) and hepatitis C virus.
Dr. Rogers earned his Master of Public Health and Ph.D. from the University of North Carolina at Chapel Hill and was a postdoctoral fellow in Clinical Microbiology at St. Jude Children’s Hospital.
Other Triangle executive moves
Cary-based SciQuest (NASDAQ:SQI) hired Mark Digman to become vice president, product marketing and strategy. Digman has 20 years of product marketing experience, most recently at SciQuest from SAS Institute. SciQuest also named Eric Zoetmulder vice president, product management. Eric has nearly 20 years of experience in product management, product marketing and professional services, and has been with SciQuest since 2006.
